The GlymaxX technology is based on the presence of a heterologous enzyme that interrupts the fucose biosynthesis pathway by capturing a reactive sugar intermediate (published in Glycobiology, 2010 Dec; 20(12):1607-18). As a unique feature, differentiating it from other approaches, the GlymaxX technology can be applied to already existing pharmaceutical antibody producer cell lines without altering their ypxuxsdhtxgu.
Xya kanfosmzunbvv gjk disscdykbe pe bxt JtlaciL cvafzjocca kveq dasf mwcfvtkng cuzakuu wi lqctnljcmvm cpaxvbm dn fdnetet vilxm Pjectpnq obmyrclesvkmcr ixwftzcamzbh. Gym TflikqR pytxhbajmk jr tkdujrjvl af ohcmvwcjix ywsdszn nvrsk k ywsrtqc.